tbuckley/cabot-search huggingface dataset:
SAT0319 Severity in Systemic Lupus Erythematosus Patients: A Latent Trait Analysis
Authors: N. Molano-González, J.C. Sarmiento-Monroy, M. Rodríguez-Jiménez, R.D. Mantilla, A. Rojas-Villarraga, J.-M. Anaya
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic Lupus Erythematosus (SLE) is a complex disease which can potentially involve any organ and, therefore, has a wide range of clinical manifestations (i.e., subphenotypes) [1]. <h3>Objectives</h3> To propose a novel methodology for building an index of severity in patients with SLE. <h3>Methods</h3> A cross-sectional analytical study was done on 319 SLE patients (1997 ACR). A structural model for the latent trait in the 2pl item response theory model was fitted following the Ogasawara9s formulation [2] in order to characterize a severity construct of 17 variables. In addition, the model analyzed possible associations of the severity latent trait with other patient covariates including cardiovascular disease, age at onset of the disease, and expositional factors. <h3>Results</h3> Baseline characteristics of patients were as follows: female gender 91%, median age 37 (IQR 21) years, median duration of the disease 5 (IQR 10) years, lupus nephritis 37.3%, and central nervous system involvement in 16%. Several symptoms were excluded from the severity construct due to inconsistency according to Cronbach-Mesbah Curve including lupus nephritis, diffuse alveolar hemorrhage, and vasculitis. A total of 11 symptoms were included in the item response theory model showing three levels of disease severity (Figure 1). The only covariate registered that reaches an association with severity was coffee consumption. <h3>Conclusions</h3> Symptoms excluded due to inconsistency share the same pathogenic mechanism in SLE, which corresponds to autoantibody-driven tissue damage, and are associated with high mortality risk. The remaining symptoms are related to inflammation and vasculopathy, and in most cases, require a less aggressive immunosuppressive treatment [3]. The order of symptoms on the present scale of severity coincides with clinical experience, and the three levels of performance can be associated with low, moderate, and high severity. The present index of severity is useful for SLE patients with less severe phenotype (i.e., without nephritis, diffuse alveolar hemorrhage, and vasculitis). A further replication study is necessary to validate these results. <h3>References</h3> Tsokos GC. N Engl J Med 2011;365(22):2110–21. Ogasawara, H. Behaviormetrika;1995 22(1): 37–48. D9Cruz DP, Khamashta MA, and Hughes GR. Lancet 2007;369(9561):587–96. <h3>Disclosure of Interest</h3> None declared
Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q.
Authors: Alan F. List, Gordon W. Dewald, John M. Bennett, Aristoteles Giagounidis, Azra Raza, Eric J. Feldman, Bayard L. Powell, Peter L. Greenberg, Stephen D. Nimer, Jerome B. Zeldis, Kenton Wride, Michele Schmidt, Robert D. Knight
Journal: Blood (2006)
PWE-137 Inpatient Colonoscopy: Is Urgency a Substitute for Quality?: Abstract PWE-137 Table 1
Authors: J Schembri, N Muhammad, P Orchard, R Dennes, M Thoufeeq
Journal: Gut (2016)

<h3>Introduction</h3> Whereas colonoscopy is usually regarded as an outpatient procedure the practice of inpatient colonoscopy has nowadays become routine.<sup>1</sup> Apart from the classical indication of acute lower gastrointestinal bleeding, inpatient colonoscopy has some other clear advantages including expedited assessment and relieving waiting list pressures. <h3>Methods</h3> We conducted a retrospective cohort study looking at inpatient adult colonoscopies performed at Sheffield Teaching Hospitals over a 1 year period (Oct 2014 and Sep 2015). Inpatient colonoscopies were split as either emergency (EMI) or elective procedures (ELI), the latter usually required for anticoagulation bridging or for inpatient bowel prep. The ELI group served as a control for EMI procedures. <h3>Results</h3> 316 inpatient colonoscopies were performed over this time period (43.7% EMI,56.3% ELI). Table 1 compares patient characteristics and endoscopy outcomes between EMI and ELI procedures. Compliance to bowel prep and prep adequacy was suboptimal in both, but particularly poor in the EMI group. This is also reflected by the fact that more EMI patients went on to have an alternative investigation. Caecal intubation was also lower in the EMI group and well below accepted national standards. Polyp detection was similar in both groups. Overall 34.8% of EMI procedures were deemed diagnostic. Referral indications in order of yield were rectal bleeding (52%), abnormal radiology (44%) and change in bowel habit (38%) with abdominal pain (30%) and anaemia (15%) being the least helpful indications. The commonest pathologies identified during EMI colonoscopy were colitis (15.2%), malignancy (4.3%), vascular lesions (4.3%) and large polyps (3.6%). Length of stay from time of procedure varied widely within the EMI group with a mean of 19 days and 11.7% of patients had passed away at 3 months post procedure, none of these being procedure related deaths. <h3>Conclusion</h3> Emergency inpatient colonoscopy is clearly a useful tool with a relatively high diagnostic yield. A significant proportion of procedures are however being deemed inadequate and therefore submitting frail inpatients to unnecessary stress. The relative lengthy hospital stays and mortality rates indicate that some of these procedures might be futile and not always beneficial. We believe that apart from more consideration being given to the patients’ general wellbeing and medical state, this service should be limited to a few strict indications like rectal bleeding and suspected IBD. <h3>Reference</h3> 1. Enns R, Krygier D. The inpatient colonoscopy: A difficult endeavourendeavor. <i>Canadian Journal of Gastroenterology</i> 2008;<b>22</b>(11):900–902 <h3>Disclosure of Interest</h3> None Declared
Pre-Surgical Methylene-Blue “targeting” of Small Intrapulmonary Nodules In Patients with Haematological Malignancies: Preliminary Experience.
Authors: M. Mansour Ceesay, Ouni Jaffer, Phillip FC Lung, Michael T Marrinan, Ranjit Deshpande, Nicola Mullholland, Antonio Pagliuca, Ghulam J. Mufti, Sujal R Desai
Journal: Blood (2010)
AB0429 Pure Red Cell Aplasia in Patients from SLE Registry from The spanish Society of Rheumatology (RELESSER): Table 1
Authors: A. Lois-Iglesias, I. Rúa-Figueroa, C. Erausquin, D. Grados, A. Olivé, V. Quevedo, J. Alegre, J. Calvo, F. Lόpez-Longo, M. Galindo, F. deToro, C. Mouriño, J. Pego-Reigosa
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic Lupus Erythematosus (SLE) is an autoimmune systemic rheumatic disease that, in our area, presents hematologic manifestations in approximately 70% of cases<sup>1</sup>. Some of them are very rare, there are no large series whose analysis could provide relevant information. <h3>Objectives</h3> To study the characteristics of patients with Pure Red Cell Aplasia (PRCA) in a large sample of SLE patients. <h3>Methods</h3> SLE patients from RELESSER database were studied. We analysed the clinical and analytical SLE manifestations at 12 different domains (mucocutaneous, renal, musculoskeletal, constitutional, haematologic, vascular, cardiac, respiratory, neuropsychiatric, gastrointestinal, ophthalmic and serological) before, during and after PRCA diagnosis and until the last available assessment. We also studied activity (SELENA-SLEDAI) and damage (SLICC/ACR DI)indices at each of those times. We evaluated the treatment received, PRCA recurrences and the number of deaths by this entity. <h3>Results</h3> 3,656 patients from 45Rheumatology Units across Spain were studied. 5 cases of PRCA were found (&lt;0.5%of total) There were not viral infections in relation with the PRCA. All patients had a good response to treatment, reaching complete remission without relapses or deaths. The mean number of treatment lines (± SD)that were necessary was 2.2 (±1.01)and the mean (± SD)number of treatments used was 2.8 (±1.92). Except for the patient diagnosed with PRCA before SLE, all of them received glucocorticoids as initial treatment. Of these 4patients only 1achieved complete remission without requiring immunosuppressive therapy. The following table shows the characteristics of each patient: <h3>Conclusions</h3> PRCA is a very rare cause of anemia in SLE. In most cases it appears several years after the diagnosis of SLE. It is a serious manifestation but in our series, with a proper management showed a favourable response. <h3>References</h3> Pego-Reigosa JM et al. Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus. Lupus 2015;24:720–9. <h3>Disclosure of Interest</h3> A. Lois-Iglesias: None declared, I. Rúa-Figueroa: None declared, C. Erausquin: None declared, D. Grados: None declared, A. Olivé: None declared, V. Quevedo: None declared, J. Alegre: None declared, J. Calvo: None declared, F. Lόpez-Longo: None declared, M. Galindo: None declared, F. deToro: None declared, C. Mouriño: None declared, J. Pego-Reigosa Grant/research support from: Work supported by Spanish Society of Rheumatology, FIS/ISCIII (PI11/02857), BIOCAPS from the EU 7th Framework Programme/REGPOT-2012–2013.1 (316265), GSK, Roche, Novartis, UCB.
The Possible Role of Human Mesenchymal Stem Cells on Human Osteoclast Differentiation from CD34+ Bone Marrow Hematopoietic Progenitors.
Authors: Ali U. Ural, Ferit Avcu, Aysel Pekel, Meral Sarper, Pinar Elci, Fikret Arpaci, Mukerrem Safali, Ali Sengul
Journal: Blood (2004)
FRI0428 Epidemiology of Ankylosing Spondylitis in Taiwan: A Nationwide Population Study
Authors: M.-Y. Hsieh, C.-F. Kuo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease and there are few nationwide estimates for prevalence and incidence in Taiwan. <h3>Objectives</h3> The aim of this study was to determine trends in the incidence and prevalence of AS between 2005 and 2010 among general population of Taiwan. <h3>Methods</h3> The National Health Insurance Research Database was used to identify gout patients and to estimate the prevalence and incidence of AS for each year from 2005 to 2010. To determine the trends in prevalence, incidence and management of AS, we calculated age- and sex-standardised prevalence and incidence of gout in each calendar year from 2005 to 2010 with the population structure in year 2010 as the reference. <h3>Results</h3> A total of 54,857 cases with an AS diagnosis alive in December 2010 was identified. Men had a higher prevalence (0.28% versus 0.19%) and incidence (0.51 versus 0.33 per 1,000 person-year) of AS than women. The standardised prevalence of AS had decreased from 0.30% in 2005 to 0.24% in 2010. The incidence of AS is between 0.42 and 0.50 per 1,000 person-years during 2005 and 2010. The incidence of AS in men was low in individuals younger than 19 years of age, peaked rapidly in the ages 20 to 24 years and decreased gradually. The incidence and prevalence of regions in 2010 highest in the town of Tainan (0.6% and 1.79 per 1,000 person-years) and Ilan (1.17% and 1.52 per 1,000 person-years) than other regions. <h3>Conclusions</h3> AS is a common rheumatic disease in Taiwan with a similar prevalence to rheumatoid arthritis. <h3>Disclosure of Interest</h3> None declared
Mortality from respiratory diseases associated with opium use: a population-based cohort study
Authors: Atieh Rahmati, Ramin Shakeri, Hooman Khademi, Hossein Poutschi, Akram Pourshams, Arash Etemadi, Masoud Khoshnia, Amir Ali Sohrabpour, Ali Aliasgari, Elham Jafari, Farhad Islami, Shahryar Semnani, Abdolsamad Gharravi, Christian C Abnet, Paul D P Pharoah, Paul Brennan, Paolo Boffetta, Sanford M Dawsey, Reza Malekzadeh, Farin Kamangar
Journal: Thorax (2016)

<h3>Background</h3> Recent studies have suggested that opium use may increase mortality from cancer and cardiovascular diseases. However, no comprehensive study of opium use and mortality from respiratory diseases has been published. We aimed to study the association between opium use and mortality from respiratory disease using prospectively collected data. <h3>Methods</h3> We used data from the Golestan Cohort Study, a prospective cohort study in northeastern Iran, with detailed, validated data on opium use and several other exposures. A total of 50 045 adults were enrolled from 2004 to 2008, and followed annually until June 2015, with a follow-up success rate of 99%. We used Cox proportional hazard regression models to evaluate the association between opium use and outcomes of interest. <h3>Results</h3> During the follow-up period, 331 deaths from respiratory disease were reported (85 due to respiratory malignancies and 246 due to non-malignant aetiologies). Opium use was associated with an increased risk of death from any respiratory disease (adjusted HR 95% CI 3.13 (2.42 to 4.04)). The association was dose-dependent with a HR of 3.84 (2.61 to 5.67) for the highest quintile of cumulative opium use versus never use (P<sub>trend</sub>&lt;0.001). The HRs (95% CI) for the associations between opium use and malignant and non-malignant causes of respiratory mortality were 1.96 (1.18 to 3.25) and 3.71 (2.76 to 4.96), respectively. <h3>Conclusions</h3> Long-term opium use is associated with increased mortality from both malignant and non-malignant respiratory diseases.
Myeloid-Associated Antigen Expression Is an Adverse Factor for Complete Remission Following Induction Chemotherapy of Adult Precursor T-Lymphoblastic Leukemia/Lymphoma (T-ALL).
Authors: Murtadha Al-Khabori, Samira Samiee, Sharon Fung, Wei Xu, Joseph Brandwein, William Brien, Bruce Patterson, Hong Chang
Journal: Blood (2007)
Acute Graft-Versus-Host Disease: Clinical Presentation and Response to Therapy Following Umbilical Cord Blood Transplant.
Authors: Mukta Arora, John E. Wagner, Juliet N. Barker, Jeffrey S. Miller, Linda J. Burns, Margaret L. MacMillan, Bruce R. Blazar, Todd E. Defor, Daniel J. Weisdorf
Journal: Blood (2004)
An Accelerated CD8+, but Not CD4+, T-Cell Reconstitution Associates with a More Favorable Outcome Following HLA-Haploidentical HSCT: Results from a Retrospective Study of the Cell Therapy and Immunobiology Working Party of the EBMT
Authors: Attilio Bondanza, Loredana Ruggeri, Dimitris Ziagkos, Chiara Bonini, Christian Chabannon, Natalia Bootsman, Cora Knol-Bout, Liesbeth De Wreede, Maddalena Noviello, Lara Crucitti, Luca Vago, Alessandra Carotti, Adelmo Terenzi, Mara Merluzzi, Maria Speranza Massei, Lucia Amico, Sara Piccinelli, Joan Hendrik Veelken, Yener Koc, Peter Bader, Bernd Gruhn, Franco Locatelli, Fabio Ciceri, Antoine Toubert, Andrea Velardi
Journal: Blood (2015)
Coronary Artery Calcium to Guide a Personalized Risk-Based Approach to Initiation and Intensification of Antihypertensive Therapy
Authors: John W. McEvoy, Seth S. Martin, Zeina A. Dardari, Michael D. Miedema, Veit Sandfort, Joseph Yeboah, Matthew J. Budoff, David C. Goff, Bruce M. Psaty, Wendy S. Post, Khurram Nasir, Roger S. Blumenthal, Michael J. Blaha
Journal: Circulation (2016)

The use of atherosclerotic cardiovascular disease (ASCVD) risk to personalize systolic blood pressure (SBP) treatment goals is a topic of increasing interest. Therefore, we studied whether coronary artery calcium (CAC) can further guide the allocation of anti-hypertensive treatment intensity.We included 3733 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with SBP between 120 and 179 mm Hg. Within subgroups categorized by both SBP (120-139 mm Hg, 140-159 mm Hg, and 160-179 mm Hg) and estimated 10-year ASCVD risk (using the American College of Cardiology/American Heart Assocation pooled-cohort equations), we compared multivariable-adjusted hazard ratios for the composite outcome of incident ASCVD or heart failure after further stratifying by CAC (0, 1-100, or >100). We estimated 10-year number-needed-to-treat for an intensive SBP goal of 120 mm Hg by applying the treatment benefit recorded in meta-analyses to event rates within CAC strata.The mean age was 65 years, and 642 composite events took place over a median of 10.2 years. In persons with SBP <160 mm Hg, CAC stratified risk for events. For example, among those with an ASCVD risk of <15% and who had an SBP of either 120 to 139 mm Hg or 140 to 159 mm Hg, respectively, we found increasing hazard ratios for events with CAC 1 to 100 (1.7 [95% confidence interval, 1.0-2.6] or 2.0 [1.1-3.8]) and CAC >100 (3.0 [1.8-5.0] or 5.7 [2.9-11.0]), all relative to CAC=0. There appeared to be no statistical association between CAC and events when SBP was 160 to 179 mm Hg, irrespective of ASCVD risk level. Estimated 10-year number-needed-to-treat for a SBP goal of 120mmHg varied substantially according to CAC levels when predicted ASCVD risk <15% and SBP <160mmHg (eg, 10-year number-needed-to-treat of 99 for CAC=0 and 24 for CAC>100, when SBP 120-139mm Hg). However, few participants with ASCVD risk <5% had elevated CAC. Furthermore, 10-year number-needed-to-treat estimates were consistently low and varied less among CAC strata when SBP was 160 to 179 mm Hg or when ASCVD risk was ≥15% at any SBP level.Combined CAC imaging and assessment of global ASCVD risk has the potential to guide personalized SBP goals (eg, choosing a traditional goal of 140 or a more intensive goal of 120 mm Hg), particularly among adults with an estimated ASCVD risk of 5% to 15% and prehypertension or mild hypertension.
Second Donation of Bone Marrow; Japan Marrow Donor Program (JMDP) Experience.
Authors: Hideki Akiyama, Masamichi Hara, Masayuki Hino, Hiroshi Sao, Yasutaka Hoshi, Hitoshi Ohto, Shunro Kai, Ryoichi Ochiai, Kiyoshi Morita, Yasuo Nakao
Journal: Blood (2004)
Phase I Dose Escalating Trial of Bortezomib (Velcade®) in Combination with Idarubicin and Cytarabine in Patients with Acute Myeloid Leukemia.
Authors: Eyal C. Attar, Daniel J. DeAngelo, Karen K. Ballen, Emily Learner, Elizabeth G. Trehu, David P. Schenkein, James D. Levine, Richard M. Stone, Philip C. Amrein
Journal: Blood (2004)
Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma
Authors: Kilannin Krysiak, Felicia Gomez, Brian S. White, Matthew Matlock, Christopher A. Miller, Lee Trani, Catrina C. Fronick, Robert S. Fulton, Friederike Kreisel, Amanda F. Cashen, Kenneth R. Carson, Melissa M. Berrien-Elliott, Nancy L. Bartlett, Malachi Griffith, Obi L. Griffith, Todd A. Fehniger
Journal: Blood (2016)
Effect of Five Therapeutic Strategies on the Coagulation Defect Induced By the Thrombomodulin C.1611C&gt;a Mutation
Authors: Yesim G. Dargaud, Yohann Jourdy, Sandra Le Quellec, Coen Hemker, Theo Lindhout, Elisabetta Castoldi, Claude Negrier
Journal: Blood (2015)
Post-traumatic stress disorder in young breast cancer survivors.
Authors: Danny A. Vazquez, Shoshana M. Rosenberg, Shari I. Gelber, Kathryn Jean Ruddy, Evan Morgan, Christopher J. Recklitis, Steven E. Come, Lidia Schapira, Ann H. Partridge
Journal: Journal of Clinical Oncology (2016)

202 Background: Posttraumatic stress disorder (PTSD) is associated with morbidity and mortality in affected populations. Cancer survivors experience PTSD at a rate higher than the general population, with young age and female gender identified as risk factors. While young women with breast cancer experience greater psychosocial distress in general following diagnosis (dx), little is known about PTSD in this population. Methods: Women dx’d with Stage I-III breast cancer at age ≤ 40 were surveyed as a part of a multi-site cohort study. Demographic, treatment, psychosocial characteristics (including self-reported psychiatric conditions and use of psychiatric medications prior to dx), anxiety and depression (Hospital Anxiety and Depression Scale), fear of recurrence (Lasry Scale), and social support (Medical Outcomes Study) were assessed within 1 year after dx. PTSD was measured at 30 months post-dx using the PTSD Checklist – Civilian Version; a score ≥ 50 was considered positive for PTSD. Univariable and stepwise multivariable logistic regression were used to evaluate factors associated with PTSD. Results: 572 women were eligible for this analysis; median age at dx was 37 (range: 17-40); 87% had Stage I or II cancer. 37/572 women (6.5%) met criteria for PTSD at 30 months. Lower educational attainment, less financial comfort, less social support, stage 2 (vs. 1) disease, receipt of chemotherapy, fear of recurrence, anxiety and depression, and psychiatric comorbidities were associated (p ≤ 0.05) with PTSD in univariable analyses. Chemotherapy (OR = 3.48, 95% CI = 1.09-11.06), anxiety by HADS (OR = 20.29, 95% CI = 7.83-52.53), and psychiatric comorbidities (OR = 4.22, 95% CI = 1.40-12.74) were associated with increased likelihood of PTSD, whereas college education (OR = 0.25, 95% CI = 0.10-0.59) and greater social support (OR = 0.41, 95% CI = 0.17-0.99) appeared to be protective in multivariable analyses. Conclusions: PTSD affects a minority of young breast cancer survivors, with the prevalence in our cohort similar to that seen in other breast cancer populations. Early identification of those at risk for developing PTSD is essential for the adequate treatment of affected women and for the improvement of health outcomes and quality of life in cancer survivors.
Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Results On Survival, Progression-Free Survival, Delayed Neutropenias and Secondary Malignancies Confirm Superiority of the FCR Regimen
Authors: Kirsten Fischer, Jasmin Bahlo, Anna- Maria Fink, Raymonde Busch, Sebastian Böttcher, Jiri Mayer, Peter Dreger, Christian Maurer, Anja Engelke, Michael Kneba, Hartmut Döhner, Barbara F. Eichhorst, Clemens-Martin Wendtner, Stephan Stilgenbauer, Michael Hallek
Journal: Blood (2012)
Clinical Study of Allo-HSCT with Conditioning Regimen Containing Decitabine in the Treatment of advanced Acute Myloid Leukemia and Myelodysplastic Syndrom
Authors: Xiaojing Shi, Aining Sun, Xiaming Zhu, Huiying Qiu, Zhengming Jin, Miao Miao, Chengcheng Fu, Xiao Ma, Feng Chen, Shengli Xue, Changgeng Ruan, Wu Depei, Xiaowen Tang
Journal: Blood (2014)